Analgesia, Antidotes, Diagnostic Agents, Musculoskeletal & Surgical Preparations - This Invitation to Offer ( ITO) ****- 10 is being issued on behalf of Central Pharmacy to the open market and includes a call for pharmaceutical products classified under the following Therapeutic Classes - Analgesia Antidotes ( Poisoning & Toxicity) Diagnostic Agents Musculoskeletal System Surgical Preparations Please do not offer products which are unrelated to the Therapeutic Classes listed above. This ITO is for All
AI helper
This is an invitation to offer (ITO) for a Pharmaceutical Header Standing Offer Arrangement (PHA) with Queensland Health. The tender is for pharmaceutical products classified under specific therapeutic classes: analgesia, poisoning toxicity, diagnostic agents, musculoskeletal system surgical preparations. Offers must be lodged electronically by Monday, 15 June 2026, at 2:00 PM AEST. Key aspects include: - The ITO is for establishing a standing offer arrangement (SOA) that can be used by eligible customers across all hospital health services in Queensland. - Evaluation criteria include clinical suitability, functionality, comparative cost, supply capability, supplier capability and experience, risk management, and commitment to economic, environmental, social, and sustainable objectives. Mandatory criteria include ASIC current company extract, insurances, quality assurance, adherence to the Queensland Government Supplier Code of Conduct, TGA certifications, and coloured artwork/images. - Suppliers may be required to provide samples of the goods. Samples must be delivered within 3 business days of request to a specified address in Richlands, Queensland. - Offers must remain valid for a minimum of 12 months. - All offers must be submitted electronically via the VendorPanel website. - The principal's contact person for inquiries is Sharyn Waldock. - A complaints management process is in place. - Warranties regarding anticompetitive conduct, conflict of interest, criminal organisations, and accuracy of information are ongoing. - Suppliers are encouraged to submit alternative and innovative offers.
The bid notice states that offers must be lodged by 2:00 PM AEST on Monday, 15 June 2026.
The bid notice states that warranties are ongoing and cover anticompetitive conduct, conflict of interest, criminal organisations, and accuracy of information.
The bid notice states that the principal is not evaluating offers on the sole criterion of price. The criteria include clinical suitability, functionality, comparative cost, ability to meet supply requirements, supplier capability, experience and past performance, risk management strategies, and commitment to economic, environmental, sustainable, and social objectives.
The bid notice states that mandatory criteria include ASIC current company extract, insurances, quality assurance as per AS/NZS ISO 9001:2016 or licence to wholesale or TGA licence to manufacture, adherence to the Queensland Government Supplier Code of Conduct, TGA certifications for all products, and coloured artwork/images for all products.
The bid notice states that as part of its offer, the supplier must provide samples if requested of the required goods. Samples must be submitted in accordance with the requirements outlined, and non-compliance may result in an offer being excluded.
